A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs IdeS (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms HighIdeS
- Sponsors Hansa Medical AB
- 22 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
- 22 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 20 Jul 2017 According to a Hansa Medical media release, the company expects to enrol and treat all patients by the end of 2017.